Potential New Pharmacological Agents Derived From Medicinal Plants for the Treatment of Pancreatic Cancer

被引：33

作者：

Azimi, Haniye ^{[1
]}

Khakshur, Ali Asghar ^{[1
]}

Abdollahi, Mohammad ^{[1
]}

Rahimi, Roja ^{[2
]}

机构：

[1] Univ Tehran Med Sci, Dept Pharmacol & Toxicol, Pharmaceut Sci Res Ctr, Fac Pharm, Tehran 1417653761, Iran

[2] Univ Tehran Med Sci, Fac Tradit Med, Dept Tradit Pharm, Tehran 1417653761, Iran

来源：

PANCREAS | 2015年 / 44卷 / 01期

关键词：

medicinal plants; pancreas; pancreatic cancer; pharmacological mechanisms; phytochemical compounds; systematic review;

D O I：

10.1097/MPA.0000000000000175

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

100201 [内科学];

摘要：

In the present article, we reviewed plants and phytochemical compounds demonstrating beneficial effects in pancreatic cancer to find new sources of pharmaceutical agents. For this purpose, Scopus, PubMed, Web of Science, and Google scholar were searched for plants or herbal components with beneficial effects in the treatment of pancreatic cancer. Data were collected up to January 2013. The search terms were plant, herb, herbal therapy, or phytotherapy and pancreatic cancer or pancreas. All of the human in vivo and in vitro studies were included. According to studies, among diverse plants and phytochemicals, 12 compounds including apigenin, genistein, quercetin, resveratrol, epigallocatechin gallate, benzyl isothiocyanate, sulforaphane, curcumin, thymoquinone, dihydroartemisinin, cucurbitacin B, and perillyl alcohol have beneficial action against pancreatic cancer cells through 4 or more mechanisms. Applying their plausible synergistic effects can be an imperative approach for finding new efficient pharmacological agents in the treatment of pancreatic cancer.

引用

页码：11 / 15

页数：5

共 167 条

[1]

Michaud D.S., Epidemiology of pancreatic cancer, Minerva Chir., 59, pp. 99-111, (2004)

[2]

Li J., Saif M.W., Advancements in the management of pancreatic cancer, JOP., 10, pp. 109-117, (2009)

[3]

Dunphy E.P., Pancreatic cancer: A review and update, Clin J Oncol Nurs., 12, pp. 735-741, (2008)

[4]

Lakatos G., Tulassay Z., The epidemiology of pancreatic cancer, Orv Hetil., 151, pp. 1816-1822, (2010)

[5]

Lowenfels A.B., Maisonneuve P., Epidemiology and risk factors for pancreatic cancer, Best Pract Res Clin Gastroenterol., 20, pp. 197-209, (2006)

[6]

Saif M.W., Pancreatic neoplasm in 2011: An update, JOP., 12, pp. 316-321, (2011)

[7]

Koido S., Homma S., Takahara A., Et al., Current immunotherapeutic approaches in pancreatic cancer, Clin Dev Immunol., 2011, (2011)

[8]

Conroy T., Gavoille C., Samalin E., Et al., The role of the FOLFIRINOX regimen for advanced pancreatic cancer, Curr Oncol Rep., 15, pp. 182-189, (2013)

[9]

Melstrom L.G., Salabat M.R., Ding X.Z., Et al., Apigenin down-regulates the hypoxia response genes: HIF-1?, GLUT-1, and VEGF in human pancreatic cancer cells, J Surg Res., 167, pp. 173-181, (2011)

[10]

He L., Wu Y., Lin L., Et al., Hispidulin, a small flavonoid molecule, suppresses the angiogenesis and growth of human pancreatic cancer by targeting vascular endothelial growth factor receptor 2-mediated PI3K/Akt/mTOR signaling pathway, Cancer Sci., 102, pp. 219-225, (2011)

← 1 2 3 4 5 6 7 8 9 10 →